# |
PMID |
Sentence |
1 |
19304955
|
Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity.
|
2 |
19304955
|
IL-28B belongs to the newly described interferon lambda (IFNlambda) family of cytokines, and has not yet been assessed for its potential ability to influence adaptive immune responses or act as a vaccine adjuvant.
|
3 |
19304955
|
We show here that IL-28B, like IL-12, is capable of robustly enhancing adaptive immunity.
|
4 |
19304955
|
We also show that IL-28B, unlike IL-12, is able to increase the percentage of splenic CD8(+) T cells in vaccinated animals, and that these cells are more granular and have higher antigen-specific cytolytic degranulation compared with cells taken from animals that received IL-12 as an adjuvant.
|
5 |
25503988
|
IL-28B, a member of the interferon (IFN)-λ family, has variable expression due to single nucleotide polymorphisms (SNPs).
|
6 |
25503988
|
While type-I IFNs are well known to modulate adaptive immunity, the impact of IL-28B on B- and T-cell vaccine responses is unclear.
|
7 |
25503988
|
In vitro, recombinant IL-28B increased Th1-cytokines (e.g.
|
8 |
25503988
|
IL-4, IL-5, and IL-13), H1N1-stimulated B-cell proliferation (reduced 70%), and IgG-production (reduced>70%).
|
9 |
25503988
|
Since IL-28B inhibited B-cell responses, we designed antagonistic peptides to block the IL-28 receptor α-subunit (IL28RA).
|
10 |
26038748
|
Common single nucleotide polymorphisms (SNPs) in the IFNL3, IFNL4 and the IFNL receptor α-subunit genes have been strongly associated with IFN-α-based treatment of chronic hepatitis C virus infection.
|